Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

Efsen, 2011, Modern treatment of adult short bowel syndrome patients, Minerva Gastroenterol Dietol, 57, 405 Spiller, 1988, Further characterisation of the ‘ileal brake’ reflex in man—effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY, Gut, 29, 1042, 10.1136/gut.29.8.1042 Nightingale, 1993, Disturbed gastric emptying in the short bowel syndrome. Evidence for a ‘colonic brake’, Gut, 34, 1171, 10.1136/gut.34.9.1171 Jeppesen, 1999, Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure, Gut, 45, 559, 10.1136/gut.45.4.559 Drucker, 1996, Induction of intestinal epithelial proliferation by glucagon-like peptide 2, Proc Natl Acad Sci USA, 93, 7911, 10.1073/pnas.93.15.7911 Wojdemann, 1998, Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs, Scand J Gastroenterol, 33, 828, 10.1080/00365529850171486 Wojdemann, 1999, Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2, J Clin Endocrinol Metab, 84, 2513, 10.1210/jcem.84.7.5840 Bremholm, 2011, The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients, Regul Pept, 168, 32, 10.1016/j.regpep.2011.03.003 Cani, 2009, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability, Gut, 58, 1091, 10.1136/gut.2008.165886 Brubaker, 1997, Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2, Am J Physiol, 272, E1050 Jeppesen, 2005, Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients, Gut, 54, 1224, 10.1136/gut.2004.061440 Norholk, 2012, Treatment of adult short bowel syndrome patients with teduglutide, Expert Opin Pharmacother, 13, 235, 10.1517/14656566.2012.644787 Jeppesen, 2011, Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrom, Gut, 60, 902, 10.1136/gut.2010.218271 Gutniak, 1992, Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus, N Engl J Med, 326, 1316, 10.1056/NEJM199205143262003 Kunkel, 2011, Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome, Neurogastroenterol Motil, 23, 739-e328, 10.1111/j.1365-2982.2011.01723.x Jeppesen, 2001, Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon, Gastroenterology, 120, 806, 10.1053/gast.2001.22555 Jeppesen, 1998, Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection, Gut, 43, 763, 10.1136/gut.43.6.763 Knop, 2007, The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance, Regul Pept, 144, 123, 10.1016/j.regpep.2007.07.002 Jeppesen, 2009, Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function, Gastroenterol Res Pract, 2009, 616054 Jeppesen, 2012, Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome, Therap Adv Gastroenterol, 5, 159, 10.1177/1756283X11436318 Jeppesen, 2009, Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life, Gastroenterol Res Pract, 2009, 425759